This study was performed according to the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, China.

The following inclusion criteria were required to be included in the study: (1) histologically confirmed diagnosis of cervical cancer or CIN; (2) positive result of the HPV58 DNA test. Exclusion criteria included previous treatment for the cervical disease (including loop electrosurgical excision procedure (LEEP), cold-knife conization, cryotherapy, LASER therapy, or hysterectomy, prior chemotherapy or radiation treatment for cervical neoplasia, pregnancy, HIV infection, previous or co-existence of other malignant diseases. 25 cervical cancer patients and 42 CIN patients who were HPV58-positive detected by polymerase chain reaction (PCR) were included between January 2009 and August 2016 from Sir Run Run Shaw Hospital of Zhejiang University School of Medicine. Written informed consent was obtained from all the participants. Formalin-fixed and paraffin-embedded (FFPE) specimens from cervical cancer patients and CIN patients diagnosed according to the WHO classification of tumors of female reproductive organs by the Division of Pathology and were collected by the Departments of Obstetrics and Gynecology, Sir Run Run Shaw Hospital. Authors could access information that could identify individual participants during and after data collection.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.